Short course palliative radiotherapy in the management of choroidal metastasis: An effective technique since ages  by Roy, Soumyajit et al.
Journal of the Egyptian National Cancer Institute (2016) 28, 49–53Cairo University
Journal of the Egyptian National Cancer Institute
www.elsevier.com/locate/jnci
www.sciencedirect.comCase ReportShort course palliative radiotherapy in the
management of choroidal metastasis: An eﬀective
technique since ages* Corresponding author.
E-mail address: soumyajitroy8@gmail.com (S. Roy).
Peer review under responsibility of The National Cancer Institute, Cairo University.
http://dx.doi.org/10.1016/j.jnci.2015.07.003
1110-0362 ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Soumyajit Roy a,*, Renu Madan a, Ajay Gogia b, Koushik Tripathy c,
Dayanand Sharma a, Pramod Kumar Julka a, Goura Kishore Rath aa Department of Radiation Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences,
New Delhi 110029, India
b Department of Medical Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical
Sciences, New Delhi 110029, India
c Department of Ophthalmology, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences,
New Delhi 110029, India
Received 22 June 2015; revised 11 July 2015; accepted 11 July 2015
Available online 31 July 2015KEYWORDS
Choroidal metastasis;
Carcinoma breast;
Palliative radiotherapy;
Uveal metastasisAbstract Purpose: Uveal tract is the most common site of intra-ocular metastasis. Overall, the
reported prevalence of clinically evident uveal metastases in patients with cancer ranges from 2%
to 9%, with the majority of the cases being due to breast cancer. We aimed at evaluating the role
of palliative radiotherapy in the management of choroidal metastasis from carcinoma breast.
Materials and methods: We describe the clinico-pathologic features, treatment and outcome of ten
patients of carcinoma breast who presented to the ophthalmology department at our institution
with ocular symptoms attributable to choroidal metastasis.
Results: Nine of the patients were female while one was male. All of them presented with painless
progressive diminution of vision. Median duration of symptoms was 2.25 months. Five patients
had associated lung metastasis while bone and brain metastases were seen in three and two patients
respectively. All of them received palliative radiotherapy (RT) to the involved eye (or eye + brain) by
3D-CRT (n= 7), or 2 Dimensional technique (n= 2) or electron therapy (n= 1). Doses prescribed
were 30 Gy/10#/2 weeks (n= 8); 20 Gy/5 #/1 week (n= 2). Simultaneously they received hormonal
therapy (n= 6) or systemic chemotherapy (n= 3). After a median follow up of 18 months seven
patients had complete resolution and two patients had partial resolution of the metastases.
Conclusion: Short course palliative radiation therapy is an effective modality for the management of
choroidal metastasis in patients of carcinoma breast. In the current report it led to formidable local
control with acceptable radiation induced toxicity.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of National Cancer Institute,
Cairo University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Uveal tract is the most common site for intraocular metastasis.
The potential reason for such metastasis is the high vascular
supply of the uveal tract. Choroidal metastasis accounts for
88% of cases followed by iris and ciliary body. Breast
(37–41%), lung (7%) and colon carcinomas [1,2] are common
malignancies which throw choroidal secondaries. Multiple
treatment modalities exist for the management of choroidal
metastasis; the choice depends on the primary, the associated
systemic disease burden and the available resources.
Palliative radiation therapy has been established as a successful
local treatment for uveal metastasis. However no consensus
about the adequate dose and technique of radiation therapy
has been reached yet. We explored the option of short courseFigure 1 Left eye fundus photograph shows one yellowish lesion
at the macula and another along the infero-temporal arcade with
surrounding sub-retinal ﬂuid accumulation.
Figure 2 Optical coherence tomography shows a choroidal mass at th
at the infero-temporal arcade with surrounding sub-retinal ﬂuid (rightpalliative radiation therapy in the management of choroidal
metastasis in patients with carcinoma breast.
Description of patients
Patient demographics
We documented the demographics and treatment details of ten
patients of carcinoma breast with choroidal metastasis from
our departmental archive. The median age of the patients
was 50 years (range: 48–64 years). The female: male ratioe macula with sub-retinal ﬂuid (Left) and another sub-retinal mass
).
Figure 3 B-scan ultrasonography of a globe with choroidal
metastasis shows an echogenic choroidal mass with diffuse ill
deﬁned borders and overlying retinal detachment. A-scan shows a
100% spike suggestive of retinal detachment along with moderate
to high internal acoustic reﬂectivity of the choroidal mass.
Table 1 Showing the different histopathological features of
the primary in ten patients.
Tumour characteristics Number of patients
Size >10 cm: 2
5–10 cm: 6
<5 cm: 2
Nodes N0: 1
N + ve: 9
ER status Positive: 7
Negative: 3
PR status Positive: 6
Negative: 4
HER2neu Positive: 6
Negative: 3
Unknown: 1
Ki 67 index >15: 7
<15: 3
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diminution of vision. Median duration of symptoms was
2.25 months (range: 15 days–3 months).
Investigations
Fluorescein fundal angiography (FFA) (n= 8) (Fig. 1) was
the most commonly done investigation to establish the diagno-
sis. In FFA the most common ﬁnding was multiple pin-point
leaks (n= 7). Contrast enhanced magnetic resonance imaging
of the brain and orbits and F-18 ﬂuoro-deoxyglucose positronFigure 4 The target volume delineation and three dimensional radiatiemission tomography of the whole body were done in two
patients each. Optical coherence tomography (OCT) was the
most common adjunct investigation (n= 7) (Fig. 2). In 5
patients B mode ultrasonography was done. The common
ﬁnding on B mode ultrasonography was echogenic choroidal
mass with diffuse ill-deﬁned borders (n= 2) (Fig. 3). None
of these patients had metastasis in any other intra-ocular or
intra-orbital sites. Synchronous metastases were found in other
organs like lung (n= 5); brain (n= 2); and bone (n= 3).
Characteristics of the primary tumour
The histopathological and immunohistochemical features of
the primary tumour have been shown in Table 1. The median
time to develop choroidal metastasis was 41.25 months (range
18–72 months).
Treatment details
Seven out of ten patients received palliative RT by three
dimensional conformal RT (3D-CRT) (n= 7). Two dimen-
sional ﬂuoroscopic simulator based technique and electron
beam therapy were used in two and one patient respectively.
The commonly prescribed radiation dose regime was 30 Gy
in 10 fractions over 2 weeks (n= 8) followed by 20 Gy in 5
fractions over 1 week (n= 2). The target volume for radiation
planning consisted of the involved globe + 5 mm isotropic
margin (Fig. 4). Whole brain was included in the portal when
brain metastasis was present simultaneously. Concomitant
hormone therapy included exemestane alone (n= 1), anastro-
zole (n= 3), and a combination of exemestane and everolimuson beam placement in a patient of choroidal metastasis are shown.
Table 2 Showing the improvement in visual acuity in eight patients.
Patient serial no. At baseline 1 month after radiation completion 6 months after completion of radiation
1 6/60 6/24 6/18
2 Finger counting at 3 metres distance 6/36 6/24
3 Finger counting at 3 metres distance 6/60 6/36
4 6/18 6/9 6/6
5 Only light perception Finger counting at 3 metre distance Finger counting at 1 metres distance
6 6/18 6/9 6/6
7 Only light perception 6/60 6/60
8 6/18 6/12 6/6
9 6/36 6/36 6/36
10 Only light perception Only light perception Only light perception
Table 3 A comparative analysis of dose, fraction, local control and toxicity proﬁle of different techniques of radiotherapy.
Authors Technique No of
patients
Dose Local
control
Symptomatic
improvement
Toxicity rate
Shields et al. [4] Plaque brachytherapy 36 Tumour apex: 69 Gy;
Tumour base: 236 Gy.
94% Improvement:
19%
Stable: 39%
8%
Bellmann et al. [5] SRT/SRS 10 10–20 Gy in single fraction or
30 Gy in 10 fraction
80% N/A No persistent
toxicity
Tsina et al. [6] Proton beam therapy 63 28 CGE in two fractions 84% 47% 56%
Wiegel et al. [7] Conventional
radiatherapy
50 40 Gy in 20 fractions N/A 36% 5%
Present study Conformal radiation
technique (n= 7)
Electron therapy (n= 1)
Conventional technique
(n= 2)
10 30 Gy/10 Fractions (n= 8)
20 Gy/5 fractions (n= 2)
90% 70% No persistent
toxicity
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with lapatinib and capecitabine (n= 1), gemcitabine, pacli-
taxel and bevacizumab (n= 1) or multi-agent chemotherapy
with cyclophosphamide and vinorelbine (n= 1).
Follow-up and outcome
All patients were followed up with serial FFA and OCT done
at 3 monthly intervals. After a median follow-up of
18 months (range: 6 months–37 months) seven patients had
complete resolution (CR) and two patients had partial resolu-
tion of the metastases while one patient (with associated brain
metastasis) expired after 4.3 months. The objective response
rate (ORR) (summation of CR and PR) was 90% in our ser-
ies. Serial charting of visual acuity revealed improvement in
vision in 8 patients. In the other two patients no objective
improvement was discernible in visual acuity (Table 2). We
observed acute radiation induced conjunctivitis in 4 patients
(grade II: 3 patients; grade III: 1 patient). Two patients devel-
oped epiphora after 7 months and 9 months respectively.
Three patients developed cataract (posterior subcapsular cat-
aract), two in the same eye, and one in the opposite eye. The
median latent period for cataract formation after completion
of radiation was 17.8 months (range: 16–24 months). All of
them were treated successfully using the phaco-
emulsiﬁcation technique.Discussion
Perls was the ﬁrst person who described the ﬁrst case of chor-
oidal metastasis. In the next six decades only 230 cases were
described in the literature.
External beam radiation (EBRT) has been traditionally
used for treatment of choroidal metastasis when they fail to
regress after systemic therapies. Disappearance or regression
of lesions occurs in 85–93% of patients. The prescription dose
ranges from 30 Gy to 50 Gy [3–7]. The main disadvantages of
using radiotherapy were its side effects which may be acute or
late. The common morbidities include acute conjunctivitis,
keratitis, cataracts, exposure keratopathy, iris neovasculariza-
tion, radiation induced retinopathy and papillopathy. These
side effects have been seen in 12% of patients in the reported
series [3]. Currently various modern techniques of EBRT have
been deployed for managing choroidal metastasis like stereo-
tactic radiosurgery or fractionated stereotactic radiotherapy
or proton beam therapy. Plaque brachytherapy has also been
applied in some series. The result we observed in our study is
comparable to other series in terms of response and toxicity
though our cohort size was smaller than others (Table 3).
Use of conformal technique and electron beam radiation
precluded emergence of any late toxicities.
Multiple other local treatment modalities have emerged in
the present era. Four case reports have described the use of
Palliative radiotherapy in choroidal metastasis 53intravitreal bevacizumab in patients with choroidal metastasis
despite systemic therapy. In all four case reports, lesions
regressed and retinal detachments resolved after one injection
of bevacizumab [8].
Laser photocoagulation, photodynamic therapy,
transpupillary thermotherapy, cryotherapy, local excision
and even enucleation have been used as other local treatment
modalities [9,10]. But some of these patients needed multiple
treatment sessions or further radiation therapy [10] to achieve
adequate local control. Complete loss of vision in a substantial
number of patients has been another cause of worry for these
modalities. Finally external beam radiation is still a cost effec-
tive regimen with respect to these emerging techniques.
The current study has its own limitations. The underlying
bias owing to the heterogeneity of treatment regimens cannot
be neglected. However one must accept the difﬁculties of
carrying out a uniform prospective trial for such a rare disease
entity. In a resource limited developing country like ours, pal-
liative radiotherapy is still an acceptable and feasible option. It
yields commendable treatment compliance and good response
rate at the cost of acceptable morbidities. The overall cost
effectiveness of this short course palliative EBRT regimen
makes it worthwhile to use in such a resource constrained
set-up.
Conclusion
Palliative radiation stands tall in spite of emergence of other
local treatment techniques and advancement of systemic ther-
apies in the management of choroidal metastasis. It provides
superior local control and symptomatic improvement with
minimal toxicity. It is non-invasive, cost-effective, and has bet-
ter compliance. This option merits more judicious expedition
in a developing nation like ours.
Financial disclosure
None.Conﬂicts of interest
None.
References
[1] Fernandes BF, Fernandes LH, Burnier Jr MN. Choroidal mass
as the presenting sign of small cell lung cancer. Can J
Ophthalmol 2006;41:605–8.
[2] Kreusel KM, Wiegel T, Stange M, Bornfeld N, Hinkelbein W,
Foerster MH. Choroidal metastasis in disseminated lung cancer:
frequency and risks factors. Am J Ophthalmol 2002;134:445–7.
[3] Rudoler SB, Shields CL, Corn BW, De Potter P, Hyslop T,
Curran Jr WJ, et al. Functional vision is improved in the
majority of patients treated with external-beam radiotherapy for
choroid metastases: a multivariate analysis of 188 patients. J
Clin Oncol 1997;15:1244–51.
[4] Shields CL, Shields JA, De Potter P, Quaranta M, Freire J,
Brady LW, et al. Plaque radiotherapy for the management of
uveal metastasis. Arch Ophthalmol 1997;115:203–9.
[5] Bellmann C, Fuss M, Holz FG, Debus J, Rohrschneider K,
Vo¨lcker HE, et al. Stereotactic radiation therapy for malignant
choroidal tumors: preliminary, shortterm results.
Ophthalmology 2000;107:358–65.
[6] Tsina EK, Lane AM, Zacks DN, Munzenrider JE, Collier JM,
Gragoudas ES. Treatment of metastatic tumors of the choroid
with proton beam irradiation. Ophthalmology 2005;112:337–43.
[7] Wiegel T, Bottke D, Kreusel KM, Schmidt S, Bornfeld N,
Foerster MH, et al. External beam radiotherapy of choroidal
metastases––ﬁnal results of a prospective study of the German
Cancer Society (ARO 95–08). Radiother Oncol 2002;64:13–8.
[8] Kuo IC, Haller JA, Maffrand R, Sambuelli RH, Reviglio VE.
Regression of a subfoveal choroidal metastasis of colorectal
carcinoma after intravitreous bevacizumab treatment. Arch
Ophthalmol 2008;126:1311–3.
[9] Harbour JW. Photodynamic therapy for choroidal metastasis
from carcinoid tumor. Am J Ophthalmol 2004;137:1143–5.
[10] Kiratli H, Bilgic S. Transpupillary thermotherapy in the
management of choroidal metastases. Eur J Ophthalmol
2004;14:423–9.
